Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetylsalicylic acid + escitalopram is a combination of two pharmaceutical agents. Acetylsalicylic acid (commonly known as aspirin) is a nonsteroidal anti-inflammatory drug (NSAID) that acts primarily as an irreversible inhibitor of cyclooxygenase enzymes, leading to reduced synthesis of prostaglandins and thromboxanes, which results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used mainly for the treatment of major depressive disorder and generalized anxiety disorder; it works by increasing synaptic serotonin levels through inhibition of the serotonin transporter. The combination does not have a unique brand or code name and is not marketed as a fixed-dose product but may be co-prescribed in clinical practice. Coadministration increases the risk of bleeding due to additive effects on platelet function[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylsalicylic acid + escitalopram.